AMLX vs PLX
AMLX: Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric hypoglycemia. PLX: A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies for lysosomal storage disorders.
Side-by-side fundamentals
| Metric | AMLX | PLX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.70 | $2.37 | |
| Market cap as of 2026-07-23 | $2.0B | $190M | |
| P/E as of 2026-07-23 | n/a | 12.40 | |
| PEG as of 2026-07-23 | n/a | 0.04 | |
| Net margin as of 2026-07-23 | -94.6% | +20.1% | PLX higher |
| Gross margin as of 2026-07-23 | +82.8% | +70.0% | AMLX higher |
| Operating margin as of 2026-07-23 | -99.2% | +25.9% | PLX higher |
| ROE as of 2026-07-23 | -55.7% | +28.1% | PLX higher |
| ROA as of 2026-07-23 | -50.7% | +17.8% | PLX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +27.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.5% | |
| Beta as of 2026-07-23 | -0.20 | -0.00 | |
| 1-year return as of 2026-07-22 close | +125.3% | +50.0% | AMLX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.